Targeting RUNX1 Germline Variants: Agents Under Investigation.

Area of Science:

• Hematology
• Genetics
• Oncology

Background:

• Familial Platelet Disorder with Myeloid Malignancy (FPDMM) is a genetic disorder with incompletely understood mechanisms of hematologic malignancy (HM) development.
• Current management relies on surveillance and supportive care, lacking FPDMM-specific treatments.

Purpose of the Study:

• To review emerging therapeutic strategies for FPDMM across all disease stages.
• To summarize interventions from early prevention to post-malignant transformation treatments.

Main Methods:

• Review of recent experimental strategies targeting RUNX1-FPDMM pathobiology.
• Exploration of gene correction, protein stabilization, and signaling pathway modulation.

Main Results:

• Experimental strategies include CRISPR/Cas9 for RUNX1 variants, enhancing RUNX1 protein function, and modulating downstream signaling pathways.
• Interventions targeting inflammatory pathways (JAK1/2, mTOR) show potential in mitigating HM development.
• Therapeutic approaches are multi-modal, aiming to correct gene variants, stabilize protein, and normalize signaling.

Conclusions:

• Emerging therapies for FPDMM are diverse, addressing genetic and molecular underpinnings of HM development.
• While several agents are in clinical studies, all approaches are in early stages requiring further research for clinical translation.